AI Talks Between OpenAI and FDA Hover Over Drug Evaluation—What It Means for Thai Healthcare
A U.S. FDA initiative with technology group OpenAI signals a potential shift in how medicines are evaluated. Early discussions center on AI-enabled review tools that could speed up drug assessment and influence global standards, a development watched closely in Thailand and across Asia.
For Thai readers, the possibility that AI could shorten approval times matters. Medicines today can take more than a decade to reach patients. If AI helps streamline this process in the United States, Thai regulators may feel pressure to explore similar tools, especially as Thailand positions itself as a medical hub for regional patients and innovators.
